PhuturdexDrug Pipeline Intelligence

Phuturdex › Drugs › Trilaciclib

Drugs in development · updated 30 October 2026

Trilaciclib: clinical trials and development status

Other names and codes: Cosela, Zinmyleo

NLM verified identityApproved in the US (FDA)

As of 30 October 2026 Trilaciclib is in 21 active clinical trials (recruiting or ongoing, phases I–III) for 16 diseases. The most advanced phase is III.

21Active trials
IIIMost advanced phase
16Diseases studied

Summary updated every week · data as of 30 October 2026. In Phuturdex you can follow Trilaciclib and get an email at every change or safety alert.

Sign in free →

Diseases studied

For each disease: the drug’s most advanced phase and active trials, with the reference trial on ClinicalTrials.gov.

DiseaseMost advanced phaseActive trialsReference trial
Lung small cell carcinomaIII3NCT07881705
Bladder neoplasmIII1NCT06364904
Breast neoplasmII5NCT01042379
Non-small-cell lung carcinomaII4NCT06992739
Head and neck squamous cell carcinomaII3NCT07679997
Triple-negative breast neoplasmII2NCT06027268
Endometrial neoplasmII1NCT06297811
Ewing sarcomaII1NCT06699472
Head and neck neoplasmsII1NCT06752798
HemangiosarcomaII1NCT01042379
Lung neoplasmII1NCT05578326
MetastasisII1NCT06027268
NeoplasmII1NCT01042379
NeutropeniaII1NCT05578326
OsteosarcomaII1NCT06714383
Uterine cervix neoplasmII1NCT06297811

Everything on Trilaciclib

In Phuturdex you get every trial with sponsors, countries and dates, development events, FDA and EMA approvals, patents and exclusivities, orphan designations and safety alerts, with PDF and Excel export. Free until 31 March 2027.

Open in Phuturdex →

Source: Phuturdex analysis of ClinicalTrials.gov (U.S. National Library of Medicine), FDA and EMA data, updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III. Diseases are those named by each trial (NLM MeSH terms). The estimated launch, when shown, is a Phuturdex calculation described on the Method page, not official data.

ItalianoFrançaisDeutsch